Author

J. Jackow

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. Bruckner· 1 shared A. Christiano· 1 shared A. Cramer· 1 shared A. E. Oro· 1 shared A. J. Korman· 1 shared A. M. Christiano· 1 shared A. M. De Marzo· 1 shared A. Obradovic· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Bruckner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa

G. Neumayer, J. Torkelson, S. Li, K. McCarthy, H. Zhen, M. Vangipuram, J. Jackow, A. Rami, C. Hansen, Z. Guo, S. Gaddam, A. Pappalardo, L. Li, A. Cramer, K. Roy, , A. E. Oro

This paper develops a scalable, GMP-compatible cell therapy for Dystrophic Epidermolysis Bullosa using CRISPR-corrected iPS cells to generate functional skin grafts.

bioRxiv · Feb 28, 2023 · PreprintBioengineering

Castration-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer Progression

Z. A. Lopez-Bujanda, M. C. Haffner, M. G. Chaimowitz, N. Chowdhury, N. J. Venturini, A. Obradovic, C. S. Hansen, J. Jackow, K. S. Sfanos, C. J. Bieberich, P. J. Hurley, M. J. Selby, A. J. Korman, A. M. Christiano, A. M. De Marzo, C. G. Drake

This study identifies IL-8 secretion from prostate cancer cells during castration as a driver of myeloid infiltration and cancer progression, suggesting targeting IL-8/CXCR2 with immunotherapy could delay castration resistance.

bioRxiv · May 27, 2019Immunology